CL2020003220A1 - New protein with anti-inflammatory properties - Google Patents
New protein with anti-inflammatory propertiesInfo
- Publication number
- CL2020003220A1 CL2020003220A1 CL2020003220A CL2020003220A CL2020003220A1 CL 2020003220 A1 CL2020003220 A1 CL 2020003220A1 CL 2020003220 A CL2020003220 A CL 2020003220A CL 2020003220 A CL2020003220 A CL 2020003220A CL 2020003220 A1 CL2020003220 A1 CL 2020003220A1
- Authority
- CL
- Chile
- Prior art keywords
- inflammatory properties
- new protein
- seq
- prevention
- isolated
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona una proteína aislada o recombinante que consiste en la secuencia de aminoácidos de acuerdo con la SEQ ID NO: 3 o SEQ ID: NO: 4 y su uso en la prevención o el tratamiento de una afección inflamatoria.The present invention provides an isolated or recombinant protein consisting of the amino acid sequence according to SEQ ID NO: 3 or SEQ ID: NO: 4 and its use in the prevention or treatment of an inflammatory condition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809703.0A GB201809703D0 (en) | 2018-06-13 | 2018-06-13 | Novel protein with anti-inflammatory properties |
| US16/007,742 US10858409B2 (en) | 2018-06-13 | 2018-06-13 | Protein with anti-inflammatory properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003220A1 true CL2020003220A1 (en) | 2021-10-01 |
Family
ID=66999851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003220A CL2020003220A1 (en) | 2018-06-13 | 2020-12-11 | New protein with anti-inflammatory properties |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3807303A1 (en) |
| JP (1) | JP7570324B2 (en) |
| KR (1) | KR20210039339A (en) |
| CN (2) | CN119285737A (en) |
| AU (2) | AU2019285831B2 (en) |
| BR (1) | BR112020025398A2 (en) |
| CA (1) | CA3103370A1 (en) |
| CL (1) | CL2020003220A1 (en) |
| CO (1) | CO2020016749A2 (en) |
| IL (1) | IL279350A (en) |
| MX (1) | MX2020013569A (en) |
| SG (1) | SG11202012363XA (en) |
| WO (1) | WO2019239126A1 (en) |
| ZA (1) | ZA202100115B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3255084A1 (en) * | 2022-03-31 | 2023-10-05 | Revolo Biotherapeutics Limited | Compositions and their use in methods for treating intestinal inflammation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9822115D0 (en) * | 1998-10-09 | 1998-12-02 | King S College London | Treatment of inflammatory disease |
| GB0106161D0 (en) | 2001-03-13 | 2001-05-02 | King S College London | Immunomodulators |
| DE10127572A1 (en) * | 2001-05-30 | 2002-12-05 | Pathoarray Gmbh | Tools for the diagnosis, molecular definition and therapy development of chronic inflammatory joint diseases |
| WO2006073446A2 (en) * | 2004-04-28 | 2006-07-13 | The Trustees Of The University Of Pennsylvania | Peptide-mediated protein transduction into cells the hematopoietic lineage |
| ES2525096T3 (en) * | 2005-04-19 | 2014-12-17 | Kings College London | Use of beep against bone loss and osteoporosis |
| LT2872644T (en) * | 2012-07-12 | 2017-10-10 | Uab Baltymas | Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems |
| US20140294902A1 (en) * | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
| KR101731908B1 (en) * | 2015-08-18 | 2017-05-11 | 서울대학교산학협력단 | Autophagy stimulation using p62 ZZ domain binding compounds or arginylated BiP for the prevention or treatment of neurodegenerative disease |
-
2019
- 2019-06-12 CN CN202410995156.1A patent/CN119285737A/en active Pending
- 2019-06-12 CA CA3103370A patent/CA3103370A1/en active Pending
- 2019-06-12 WO PCT/GB2019/051622 patent/WO2019239126A1/en not_active Ceased
- 2019-06-12 SG SG11202012363XA patent/SG11202012363XA/en unknown
- 2019-06-12 AU AU2019285831A patent/AU2019285831B2/en active Active
- 2019-06-12 EP EP19732414.8A patent/EP3807303A1/en active Pending
- 2019-06-12 KR KR1020207037960A patent/KR20210039339A/en not_active Withdrawn
- 2019-06-12 BR BR112020025398-7A patent/BR112020025398A2/en not_active Application Discontinuation
- 2019-06-12 JP JP2021519004A patent/JP7570324B2/en active Active
- 2019-06-12 MX MX2020013569A patent/MX2020013569A/en unknown
- 2019-06-12 CN CN201980047388.1A patent/CN112888704B/en active Active
-
2020
- 2020-12-10 IL IL279350A patent/IL279350A/en unknown
- 2020-12-11 CL CL2020003220A patent/CL2020003220A1/en unknown
- 2020-12-31 CO CONC2020/0016749A patent/CO2020016749A2/en unknown
-
2021
- 2021-01-07 ZA ZA2021/00115A patent/ZA202100115B/en unknown
-
2024
- 2024-02-15 AU AU2024200977A patent/AU2024200977B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019285831B2 (en) | 2023-11-16 |
| ZA202100115B (en) | 2022-07-27 |
| MX2020013569A (en) | 2021-05-27 |
| SG11202012363XA (en) | 2021-01-28 |
| CA3103370A1 (en) | 2019-12-19 |
| WO2019239126A1 (en) | 2019-12-19 |
| JP2021528100A (en) | 2021-10-21 |
| EP3807303A1 (en) | 2021-04-21 |
| AU2024200977B2 (en) | 2026-02-12 |
| JP7570324B2 (en) | 2024-10-23 |
| CO2020016749A2 (en) | 2021-04-08 |
| BR112020025398A2 (en) | 2021-04-06 |
| AU2024200977A1 (en) | 2024-03-07 |
| CN112888704A (en) | 2021-06-01 |
| IL279350A (en) | 2021-01-31 |
| KR20210039339A (en) | 2021-04-09 |
| CN112888704B (en) | 2024-08-02 |
| CN119285737A (en) | 2025-01-10 |
| AU2019285831A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4442816A3 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| CY1121658T1 (en) | PEPTIDES AND THEIR USE | |
| ECSP18002929A (en) | INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
| PE20220505A1 (en) | TIGIT AND PD-1/TIGIT BINDING MOLECULES | |
| MX2019006515A (en) | Compositions comprising peptide wkdeagkplvk. | |
| EA201990298A1 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| CO2021017664A2 (en) | peptides | |
| CO2017013404A2 (en) | Variants of il-37 | |
| PE20151978A1 (en) | NUTRITIONAL COMPOSITIONS CONTAINING A PEPTIDIC COMPONENT WITH ANT-INFLAMMATORY PROPERTIES AND USES OF THE SAME | |
| EA202190310A1 (en) | PROTEIN FOR INFLAMMATORY DISEASES | |
| AR120721A2 (en) | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE | |
| MX2022003758A (en) | ORAL CARE COMPOSITIONS COMPRISING BETA HOPS ACID AND AMINO ACID. | |
| PE20170955A1 (en) | NEW INSECT INHIBITOR PROTEINS | |
| MX2017006748A (en) | Amino acid compositions for the treatment of symptoms of disease. | |
| CU24609B1 (en) | FUSION PROTEIN COMPRISING A MONOMERIC FERRITIN SUBUNIT PROTEIN LINKED TO A MIC ALPHA 3 DOMAIN PROTEIN | |
| WO2019094938A3 (en) | Methods and compositions for the treatment of wounds | |
| MX2020010030A (en) | Methods and compositions comprising surfactant protein d (sp-d). | |
| AR102890A1 (en) | POLYPEPTIDES THAT INCLUDE A SEQUENCE OF G3P AMINO ACIDS OF BACTERIOPHAGUS WITHOUT GLUCOSILATION SIGNAL | |
| CL2020003220A1 (en) | New protein with anti-inflammatory properties | |
| MX2020004218A (en) | Methods and compositions for inhibiting adam10 biological activities. | |
| EA202092963A1 (en) | NEW PROTEIN WITH ANTI-INFLAMMATORY PROPERTIES | |
| MX380750B (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| MX2024001541A (en) | PROTEIN COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES. | |
| ES2722803T3 (en) | Drug containing recombinant mistletoe lectins for the treatment of malignant melanoma | |
| MX2019014697A (en) | Rage proteins for the treatment of fibrosis and dna damage mediated diseases. |